Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Liabilities and Shareholders Equity (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $583.0 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 26.42% year-over-year to $583.0 million; the TTM value through Dec 2025 reached $2.7 billion, down 20.02%, while the annual FY2025 figure was $583.0 million, 26.42% down from the prior year.
  • Liabilities and Shareholders Equity reached $583.0 million in Q4 2025 per CLDX's latest filing, down from $648.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $868.8 million in Q1 2024 and bottomed at $204.6 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $512.0 million, with a median of $452.4 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 193.72% in 2024, then dropped 26.42% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $444.7 million in 2021, then dropped by 20.67% to $352.7 million in 2022, then soared by 32.0% to $465.6 million in 2023, then soared by 70.17% to $792.3 million in 2024, then decreased by 26.42% to $583.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $583.0 million in Q4 2025, $648.4 million in Q3 2025, and $692.4 million in Q2 2025.